Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 3/2018

22.01.2018 | Original Article – Cancer Research

The use of complementary and alternative medicine by patients in routine care and the risk of interactions

verfasst von: Rachel Firkins, Hannah Eisfeld, Christina Keinki, Jens Buentzel, Andreas Hochhaus, Thorsten Schmidt, Jutta Huebner

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients suffering from cancer often make use of complementary and alternative medicine (CAM). Only few data exist on the prevalence and clinical significance of interactions of a biological CAM method and conventional drugs.

Methods

From February 2014 to March 2016, consecutive patients from five oncological practices in Germany were asked to fulfill a standardized questionnaire regarding use of CAM. Data on diagnosis, date of first diagnosis, ECOG and the past and current treatment were derived from the patients’ files. Interactions were evaluated by systematically using a database on potential interactions.

Results

From 1000 patients asked to participate, we received a total of 720 questionnaires of which 711 were completed and eligible for evaluation. 29% of the patients reported any CAM usage. Women showed a significantly higher use of CAM with 35.6 versus 23.6% of men. For 54.9% of CAM users (15.9% of all patients), we found a combination of conventional drugs and biological based CAM methods with a risk for interactions. Vitamins A, C and E were the most frequently used CAM substances in these cases (39.3%), followed by herbs with 17.5%.

Conclusion

There was a risk of interactions between a biological CAM method and conventional drugs in 54.9% of the patients using CAM. To raise knowledge on interactions a better training for doctors with respect to CAM is strongly needed. Furthermore, patients’ awareness should also be raised and communication between physician and patient on the topic improved.
Literatur
Zurück zum Zitat Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A et al (2016) Use of complementary and alternative medicine (CAM) in cancer patients: an Italian multicenter survey. Oncotarget 8(15):24401–24414PubMedCentral Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A et al (2016) Use of complementary and alternative medicine (CAM) in cancer patients: an Italian multicenter survey. Oncotarget 8(15):24401–24414PubMedCentral
Zurück zum Zitat Cassileth BR, Lucarelli CD (2003) Herb–drug interactions in oncology. BC Decker, Inc, Hamilton Cassileth BR, Lucarelli CD (2003) Herb–drug interactions in oncology. BC Decker, Inc, Hamilton
Zurück zum Zitat Hillen MA, de Haes HCJM., Stalpers LJA, Klinkenbijl JHG, Eddes EH, Butow PN et al (2014) How can communication by oncologists enhance patients’ trust? An experimental study. Ann Oncol 25(4):896–901CrossRefPubMed Hillen MA, de Haes HCJM., Stalpers LJA, Klinkenbijl JHG, Eddes EH, Butow PN et al (2014) How can communication by oncologists enhance patients’ trust? An experimental study. Ann Oncol 25(4):896–901CrossRefPubMed
Zurück zum Zitat Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187–203CrossRefPubMed Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187–203CrossRefPubMed
Zurück zum Zitat Huebner J, Muenstedt K, Muecke R, Micke O, Stoll C, Kleeberg UR et al (2013) Counseling cancer patients on complementary and alternative medicine: background, theory, and implementation of nationwide counseling facilities. Strahlenther Onkol 189(8):613–617CrossRef Huebner J, Muenstedt K, Muecke R, Micke O, Stoll C, Kleeberg UR et al (2013) Counseling cancer patients on complementary and alternative medicine: background, theory, and implementation of nationwide counseling facilities. Strahlenther Onkol 189(8):613–617CrossRef
Zurück zum Zitat Huebner J, Muenstedt K, Prott FJ, Stoll C, Micke O, Buentzel J et al (2014a) Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care (Basel Switzerland) 9(1):60–63CrossRef Huebner J, Muenstedt K, Prott FJ, Stoll C, Micke O, Buentzel J et al (2014a) Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care (Basel Switzerland) 9(1):60–63CrossRef
Zurück zum Zitat Huebner J, Micke O, Muecke R, Buentzel J, Prott FJ, Kleeberg U et al (2014b) User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 34(2):943–948PubMed Huebner J, Micke O, Muecke R, Buentzel J, Prott FJ, Kleeberg U et al (2014b) User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 34(2):943–948PubMed
Zurück zum Zitat Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler KC, Kurschat P et al (2016) Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma. Med Oncol 33(5):52CrossRefPubMed Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler KC, Kurschat P et al (2016) Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma. Med Oncol 33(5):52CrossRefPubMed
Zurück zum Zitat Loquai C, Schmidtmann I, Garzarolli M, Kaatz M, Kahler KC, Kurschat P et al (2017) Interactions from complementary and alternative medicine in patients with melanoma. Melanoma Res 27(3):238–242CrossRefPubMed Loquai C, Schmidtmann I, Garzarolli M, Kaatz M, Kahler KC, Kurschat P et al (2017) Interactions from complementary and alternative medicine in patients with melanoma. Melanoma Res 27(3):238–242CrossRefPubMed
Zurück zum Zitat Meijerman I, Beijnen JH, Schellens JHM (2006) Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11(7):742–752CrossRefPubMed Meijerman I, Beijnen JH, Schellens JHM (2006) Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11(7):742–752CrossRefPubMed
Zurück zum Zitat Pourroy B, Letellier C, Helvig A, Chanet B, De Crozals F, Alessandra C (2017). Development of a rapid risk evaluation tool for herbs/drugs interactions in cancer patients: a multicentric experience in south of France. Eur J Cancer Care 26(6):e12752CrossRef Pourroy B, Letellier C, Helvig A, Chanet B, De Crozals F, Alessandra C (2017). Development of a rapid risk evaluation tool for herbs/drugs interactions in cancer patients: a multicentric experience in south of France. Eur J Cancer Care 26(6):e12752CrossRef
Zurück zum Zitat Saxe GA, Madlensky L, Kealey S, Wu DPH, Freeman KL, Pierce JP (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the Women’s Healthy Eating and Living Study. Integr Cancer Ther 7(3):122–129CrossRefPubMedPubMedCentral Saxe GA, Madlensky L, Kealey S, Wu DPH, Freeman KL, Pierce JP (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the Women’s Healthy Eating and Living Study. Integr Cancer Ther 7(3):122–129CrossRefPubMedPubMedCentral
Zurück zum Zitat Wortmann JK, Bremer A, Eich H, Wortmann HK, Schuster A, Fühner J et al (2016) Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care. Med Oncol 33(7):78CrossRefPubMed Wortmann JK, Bremer A, Eich H, Wortmann HK, Schuster A, Fühner J et al (2016) Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care. Med Oncol 33(7):78CrossRefPubMed
Zurück zum Zitat Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E et al (2013) Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol 139(3):357–365CrossRefPubMed Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E et al (2013) Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol 139(3):357–365CrossRefPubMed
Metadaten
Titel
The use of complementary and alternative medicine by patients in routine care and the risk of interactions
verfasst von
Rachel Firkins
Hannah Eisfeld
Christina Keinki
Jens Buentzel
Andreas Hochhaus
Thorsten Schmidt
Jutta Huebner
Publikationsdatum
22.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2587-7

Weitere Artikel der Ausgabe 3/2018

Journal of Cancer Research and Clinical Oncology 3/2018 Zur Ausgabe

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.